These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 36559052)

  • 1. Cyclodextrins: Only Pharmaceutical Excipients or Full-Fledged Drug Candidates?
    Kovacs T; Nagy P; Panyi G; Szente L; Varga Z; Zakany F
    Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclodextrins in pharmaceutical formulations II: solubilization, binding constant, and complexation efficiency.
    Jambhekar SS; Breen P
    Drug Discov Today; 2016 Feb; 21(2):363-8. PubMed ID: 26687191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization.
    Loftsson T; Brewster ME
    J Pharm Sci; 1996 Oct; 85(10):1017-25. PubMed ID: 8897265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclodextrins in pharmaceutical formulations I: structure and physicochemical properties, formation of complexes, and types of complex.
    Jambhekar SS; Breen P
    Drug Discov Today; 2016 Feb; 21(2):356-62. PubMed ID: 26686054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclodextrins in drug delivery.
    Loftsson T; Jarho P; Másson M; Järvinen T
    Expert Opin Drug Deliv; 2005 Mar; 2(2):335-51. PubMed ID: 16296758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical techniques for characterization of cyclodextrin complexes in aqueous solution: a review.
    Mura P
    J Pharm Biomed Anal; 2014 Dec; 101():238-50. PubMed ID: 24680374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Potential of Cyclodextrins as Novel Active Pharmaceutical Ingredients: A Short Overview.
    di Cagno MP
    Molecules; 2016 Dec; 22(1):. PubMed ID: 28029138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amphiphilic cyclodextrin nanoparticles.
    Varan G; Varan C; Erdoğar N; Hıncal AA; Bilensoy E
    Int J Pharm; 2017 Oct; 531(2):457-469. PubMed ID: 28596142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclodextrins as Drug Carriers in Pharmaceutical Technology: The State of the Art.
    Conceicao J; Adeoye O; Cabral-Marques HM; Lobo JMS
    Curr Pharm Des; 2018; 24(13):1405-1433. PubMed ID: 29256342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclodextrins as pharmaceutical solubilizers.
    Brewster ME; Loftsson T
    Adv Drug Deliv Rev; 2007 Jul; 59(7):645-66. PubMed ID: 17601630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases.
    Coisne C; Tilloy S; Monflier E; Wils D; Fenart L; Gosselet F
    Molecules; 2016 Dec; 21(12):. PubMed ID: 27999408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclodextrins, blood-brain barrier, and treatment of neurological diseases.
    Vecsernyés M; Fenyvesi F; Bácskay I; Deli MA; Szente L; Fenyvesi É
    Arch Med Res; 2014 Nov; 45(8):711-29. PubMed ID: 25482528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclodextrins: an overview of the complexation of pharmaceutical proteins.
    Varca GH; Andréo-Filho N; Lopes PS; Ferraz HG
    Curr Protein Pept Sci; 2010 Jun; 11(4):255-63. PubMed ID: 20222865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of cyclodextrins on the proliferation of HaCaT keratinocytes in vitro.
    Hipler UC; Schönfelder U; Hipler C; Elsner P
    J Biomed Mater Res A; 2007 Oct; 83(1):70-9. PubMed ID: 17380497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between cyclodextrins and cellular components: Towards greener medical applications?
    Leclercq L
    Beilstein J Org Chem; 2016; 12():2644-2662. PubMed ID: 28144335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclodextrins and Iatrogenic Hearing Loss: New Drugs with Significant Risk.
    Crumling MA; King KA; Duncan RK
    Front Cell Neurosci; 2017; 11():355. PubMed ID: 29163061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential mode of cholesterol inclusion with 2-hydroxypropyl-cyclodextrins increases safety margin in treatment of Niemann-Pick disease type C.
    Yamada Y; Ishitsuka Y; Kondo Y; Nakahara S; Nishiyama A; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Kamei S; Shuto T; Kai H; Hayashino Y; Sugita M; Kikuchi T; Hirata F; Miwa T; Takeda H; Orita Y; Seki T; Ohta T; Kurauchi Y; Katsuki H; Matsuo M; Higaki K; Ohno K; Matsumoto S; Era T; Irie T
    Br J Pharmacol; 2021 Jul; 178(13):2727-2746. PubMed ID: 33782944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-assembled cyclodextrin aggregates and nanoparticles.
    Messner M; Kurkov SV; Jansook P; Loftsson T
    Int J Pharm; 2010 Mar; 387(1-2):199-208. PubMed ID: 19963052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ester-Based Hydrophilic Cyclodextrin Nanosponges for Topical Ocular Drug Delivery.
    Hayiyana Z; Choonara YE; Makgotloe A; du Toit LC; Kumar P; Pillay V
    Curr Pharm Des; 2016; 22(46):6988-6997. PubMed ID: 27981908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclodextrins in topical drug formulations: theory and practice.
    Loftsson T; Masson M
    Int J Pharm; 2001 Aug; 225(1-2):15-30. PubMed ID: 11489551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.